LumiThera said today that it inked a deal with ophthalmology distributor Miloftalmica to be the exclusive distributor of the Valeda light delivery system, intended to treat dry age-related macular degeneration, across Italy.
Therapy using the Valeda light delivery system consists of a series of light-based treatments to the retinal cells, which Seattle-based LumiThera claims improves energy production and can be used to address inflammation, ischemia and metabolic dysfunction that contribute to the disease.
“Our new exciting partnership with LumiThera is fully consistent with the strategy and growth objectives of Miloftalmica, combining innovation and excellence in technology. LumiThera’s breakthrough light delivery system is a value added to Miloftalmica’s product portfolio. LumiThera indeed enables us to offer the first approved treatment for people suffering from dry AMD, the leading cause of adult blindness worldwide,” Miloftalmica CEO Andrea Pagani said in a prepared statement.
“The distribution agreement with Miloftalmica allows LumiThera to expand commercialization in Europe and establishes a collaboration with a partner providing complementary diagnostic and imaging technologies to our treatment for dry AMD. Miloftalmica is a leader in providing innovative technologies to the ophthalmologist and we are excited to be working with them to provide our treatment for dry AMD,” LumiThera prez & CEO Clark Tedford said in a press release.